PI3K/AKT/mTOR通路
蛋白激酶B
RPTOR公司
信号转导
mTORC2型
癌症研究
生物
药理学
细胞生物学
mTORC1型
作者
Rupali Mohite,Gaurav Doshi
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2024-03-01
卷期号:24 (3): 231-244
标识
DOI:10.2174/1568009623666230801094826
摘要
The PI3K/Akt/mTOR pathway modulates cell growth, proliferation, metabolism, and movement. Moreover, significant studies have shown that the genes involved in this pathway are frequently activated in human cancer. Observational and computational modeling of the PI3K/AKt/mTOR pathway inhibitors has been explored in clinical trials. It has been observed that the effectiveness and safety evidence from clinical studies and various inhibitors of this route have been given FDA approval. In this review article, we focused on the processes behind the overactivation of PI3K/Akt/mTOR signaling in cancer and provided an overview of PI3K/Akt/mTOR inhibitors as either individual drugs or a combination of different doses of drugs for different types of cancer. Furthermore, the review discusses the biological function and activation of the PI3K/AKt/mTOR signaling and their role in the development of cancers. Additionally, we discussed the potential challenges and corresponding prediction biomarkers of response and resistance for PI3K/Akt/mTOR inhibitor development. The article focuses on the most current breakthroughs in using the PI3K/Akt/mTOR pathway to target certain molecules.
科研通智能强力驱动
Strongly Powered by AbleSci AI